PreOmics is a spin-off of the Max-Planck-Institute of Biochemistry, founded in 2016 by Dr G. Pichler and Dr N.A. Kulak, current CEOs, with the mission of developing and producing innovative solutions to revolutionize and standardize Mass Spectrometry (MS)-based protein analysis. Despite the short history of PreOmics, they have built up an experienced and dynamic team of 25 people with multidisciplinary expertise in assay development, product development, quality control, and commercialization. The company brought its first product to the market in 2016, and since then, they have successfully developed and commercialized other proprietary solutions.

Mass spectrometry (MS) – based proteomics allows the sensitive and accurate quantification of almost complete proteomes of complex biological fluids and tissues.

PreOmics develops:

  • Technologies
  • Assays
  • Consumables

to enable and establish MS-based proteomics in research, biomarker discovery, and clinical diagnostics.

Scroll to Top